Lipocine to Present at H.C. Wainwright 27th Annual Global Investment Conference
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 05 2025
0mins
Source: PRnewswire
Company Presentation: Lipocine Inc. will present and meet with investors at the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025, with presentations available from 7:00 a.m. EDT on September 5, 2025.
Innovative Drug Development: Lipocine is focused on developing oral delivery biopharmaceuticals, with candidates targeting conditions such as postpartum depression, epilepsy, essential tremor, obesity management, and liver cirrhosis, while also exploring partnership opportunities for several of its drug candidates.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LPCN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LPCN
Wall Street analysts forecast LPCN stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for LPCN is 6.88 USD with a low forecast of 6.75 USD and a high forecast of 7.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 10.380
Low
6.75
Averages
6.88
High
7.00
Current: 10.380
Low
6.75
Averages
6.88
High
7.00
About LPCN
Lipocine Inc. is a biopharmaceutical company leveraging its proprietary technology platform to enable effective oral delivery of therapeutics. The Company’s clinical development candidates include: LPCN 1154, oral brexanolone, for the treatment of postpartum depression, LPCN 2101, for the treatment of epilepsy, LPCN 2203, an oral candidate targeted for the management of essential tremor, LPCN 2401, an oral proprietary anabolic androgen receptor agonist for improved body composition in obesity management, and LPCN 1148, for the management of decompensated cirrhosis. It is also developing LPCN 1107, for the prevention of preterm birth, LPCN 1154, for rapid relief of postpartum depression, and LPCN 1144, for the treatment of metabolic dysfunction-associated steatohepatitis. Its product candidate, TLANDO, is a novel oral prodrug of testosterone containing testosterone undecanoate developed by the Company.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Doseology Sciences Partners with McKinney to Enhance Regulatory Compliance Strategy
- Market Growth: The consumer healthcare market is projected to reach $362 billion in 2026, prompting companies to prioritize regulatory certainty as a key component of their business strategies in a competitive landscape.
- Increased M&A Activity: A 12% rise in merger activity is anticipated in 2026 as companies pursue acquisitions to enhance technological efficiency, underscoring the critical need for thorough due diligence in navigating federal risks.
- Strategic Partnership: Doseology has partnered with McKinney Regulatory Science Advisors to expedite product development and market access through expert FDA compliance consulting, ensuring alignment with regulatory expectations.
- Market Outlook: Doseology aims to enter a global pouch market expected to exceed $69.46 billion by 2032, advancing towards commercialization with a clear regulatory strategy and secured manufacturing infrastructure.
Continue Reading
Doseology Sciences Partners with McKinney to Enhance Regulatory Compliance Strategy
- Market Growth: The consumer healthcare market is projected to reach $362 billion in 2026, with companies increasingly prioritizing regulatory certainty to navigate competitive pressures, highlighting compliance's critical role in business strategy.
- Increased M&A Activity: A 12% rise in merger activity is expected in 2026 as companies consolidate to manage cost pressures, underscoring the importance of thorough due diligence in successful transactions.
- Strategic Partnership: Doseology has partnered with McKinney Regulatory Science Advisors to leverage expert FDA compliance guidance, aiming to accelerate product development and enhance competitiveness in regulated markets.
- Market Outlook: Doseology aims to enter a global pouch market projected to exceed $69.46 billion by 2032, indicating the company's strategic positioning in emerging consumer trends.
Continue Reading